1
|
Risinskaya N, Gladysheva M, Abdulpatakhov A, Chabaeva Y, Surimova V, Aleshina O, Yushkova A, Dubova O, Kapranov N, Galtseva I, Kulikov S, Obukhova T, Sudarikov A, Parovichnikova E. DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic Leukemia: Focus on the Genes Involved. Int J Mol Sci 2023; 24:17602. [PMID: 38139431 PMCID: PMC10744257 DOI: 10.3390/ijms242417602] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2023] [Revised: 12/08/2023] [Accepted: 12/14/2023] [Indexed: 12/24/2023] Open
Abstract
The landscape of chromosomal aberrations in the tumor cells of the patients with B-ALL is diverse and can influence the outcome of the disease. Molecular karyotyping at the onset of the disease using chromosomal microarray (CMA) is advisable to identify additional molecular factors associated with the prognosis of the disease. Molecular karyotyping data for 36 patients with Ph-negative B-ALL who received therapy according to the ALL-2016 protocol are presented. We analyzed copy number alterations and their prognostic significance for CDKN2A/B, DMRTA, DOCK8, TP53, SMARCA2, PAX5, XPA, FOXE1, HEMGN, USP45, RUNX1, NF1, IGF2BP1, ERG, TMPRSS2, CRLF2, FGFR3, FLNB, IKZF1, RUNX2, ARID1B, CIP2A, PIK3CA, ATM, RB1, BIRC3, MYC, IKZF3, ETV6, ZNF384, PTPRJ, CCL20, PAX3, MTCH2, TCF3, IKZF2, BTG1, BTG2, RAG1, RAG2, ELK3, SH2B3, EP300, MAP2K2, EBI3, MEF2D, MEF2C, CEBPA, and TBLXR1 genes, choosing t(4;11) and t(7;14) as reference events. Of the 36 patients, only 5 (13.8%) had a normal molecular karyotype, and 31 (86.2%) were found to have various molecular karyotype abnormalities-104 deletions, 90 duplications or amplifications, 29 cases of cnLOH and 7 biallelic/homozygous deletions. We found that 11q22-23 duplication involving the BIRC3, ATM and MLL genes was the most adverse prognostic event in the study cohort.
Collapse
Affiliation(s)
- Natalya Risinskaya
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Maria Gladysheva
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Abdulpatakh Abdulpatakhov
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Yulia Chabaeva
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Valeriya Surimova
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Olga Aleshina
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Anna Yushkova
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Olga Dubova
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
- Institute of Biodesign and Modeling of Complex Systems, I.M. Sechenov First Moscow State Medical University, 119991 Moscow, Russia
| | - Nikolay Kapranov
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Irina Galtseva
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Sergey Kulikov
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Tatiana Obukhova
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Andrey Sudarikov
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| | - Elena Parovichnikova
- National Medical Research Center for Hematology, 125167 Moscow, Russia; (M.G.); (A.A.); (Y.C.); (V.S.); (O.A.); (A.Y.); (O.D.); (N.K.); (I.G.); (S.K.); (A.S.); (E.P.)
| |
Collapse
|
2
|
Soloveva M, Solovev M, Nikulina E, Risinskaya N, Biderman B, Yakutik I, Obukhova T, Mendeleeva L. Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma. Genes (Basel) 2023; 14:genes14020351. [PMID: 36833278 PMCID: PMC9957234 DOI: 10.3390/genes14020351] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2022] [Revised: 01/21/2023] [Accepted: 01/26/2023] [Indexed: 01/31/2023] Open
Abstract
Multiple myeloma (MM) is characterized by heterogeneity of tumor cells. The study of tumor cells from blood, bone marrow, plasmacytoma, etc., allows us to identify similarities and differences in tumor lesions of various anatomical localizations. The aim of this study was to compare the loss of heterozygosity (LOH) by tumor cells by assessing STR profiles of different MM lesions. We examined paired samples of plasma circulating tumor DNA (ctDNA) and CD138+ bone marrow cells in MM patients. For patients with plasmacytomas (66% of 38 patients included), the STR profile of plasmacytomas was also studied when biopsy samples were available. Diverse patterns of LOH were found in lesions of different localization for most patients. LOH in plasma ctDNA, bone marrow, and plasmacytoma samples was found for 55%, 71%, and 100% of patients, respectively. One could expect a greater variety of STR profiles in aberrant loci for patients with plasmacytomas. This hypothesis was not confirmed-no difference in the frequency of LOH in MM patients with or without plasmacytomas was found. This indicates the genetic diversity of tumor clones in MM, regardless of the presence of extramedullar lesions. Therefore, we conclude that risk stratification based on molecular tests performed solely on bone marrow samples may not be sufficient for all MM patients, including those without plasmacytomas. Due to genetic heterogeneity of MM tumor cells from various lesions, the high diagnostic value of liquid biopsy approaches becomes obvious.
Collapse
|
3
|
Risinskaya N, Kozhevnikova Y, Gavrilina O, Chabaeva J, Kotova E, Yushkova A, Isinova G, Zarubina K, Obukhova T, Kulikov S, Julhakyan H, Sudarikov A, Parovichnikova E. Loss of Heterozygosity in the Tumor DNA of De Novo Diagnosed Patients Is Associated with Poor Outcome for B-ALL but Not for T-ALL. Genes (Basel) 2022; 13:genes13030398. [PMID: 35327952 PMCID: PMC8952291 DOI: 10.3390/genes13030398] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2022] [Revised: 02/16/2022] [Accepted: 02/21/2022] [Indexed: 11/29/2022] Open
Abstract
Despite the introduction of new technologies in molecular diagnostics, one should not underestimate the traditional routine methods for studying tumor DNA. Here we present the evidence that short tandem repeat (STR) profiling of tumor DNA relative to DNA from healthy cells might identify chromosomal aberrations affecting therapy outcome. Tumor STR profiles of 87 adult patients with de novo Ph-negative ALL (40 B-ALL, 43 T-ALL, 4 mixed phenotype acute leukemia (MPAL)) treated according to the “RALL-2016” regimen were analyzed. DNA of tumor cells was isolated from patient bone marrow samples taken at diagnosis. Control DNA samples were taken from the buccal swab or the blood of patients in complete remission. Overall survival (OS) analysis was used to assess the independent impact of the LOH as a risk factor. Of the 87 patients, 21 were found with LOH in various STR loci (24%). For B-ALL patients, LOH (except 12p LOH) was an independent risk factor (OS hazard ratio 3.89, log-rank p-value 0.0395). In contrast, for T-ALL patients, the OS hazard ratio was 0.59 (log-rank p-value 0.62). LOH in particular STR loci measured at the onset of the disease could be used as a prognostic factor for poor outcome in B-ALL, but not in T-ALL.
Collapse
Affiliation(s)
- Natalya Risinskaya
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Yana Kozhevnikova
- School of Medicine, Lomonosov Moscow State University, 27-1, Lomonosovsky Prospect, 119991 Moscow, Russia;
| | - Olga Gavrilina
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Julia Chabaeva
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Ekaterina Kotova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Anna Yushkova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Galina Isinova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Ksenija Zarubina
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Tatiana Obukhova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Sergey Kulikov
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Hunan Julhakyan
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| | - Andrey Sudarikov
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
- Correspondence:
| | - Elena Parovichnikova
- National Research Center for Hematology, Novy Zykovski Lane, 4a, 125167 Moscow, Russia; (N.R.); (O.G.); (J.C.); (E.K.); (A.Y.); (G.I.); (K.Z.); (T.O.); (S.K.); (H.J.); (E.P.)
| |
Collapse
|
4
|
Gorodetskiy V, Probatova N, Obukhova T, Vasilyev V. Analysis of prognostic factors in diffuse large B-cell lymphoma associated with rheumatic diseases. Lupus Sci Med 2021; 8:8/1/e000561. [PMID: 34785569 PMCID: PMC8596057 DOI: 10.1136/lupus-2021-000561] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2021] [Accepted: 10/22/2021] [Indexed: 12/23/2022]
Abstract
Objective The risk of developing diffuse large B-cell lymphoma (DLBCL) is increased in many rheumatic diseases (RDs). It is possible that RD-associated DLBCL is a distinct subset within the category of ‘DLBCL’, exhibiting characteristic biological features and clinical behaviour. However, information on RD-associated DLBCL is limited. Methods We searched the V.A. Nasonova Research Institute of Rheumatology (Russia) database from 1996 to 2021 for patients with RDs and coexisting DLBCL. Prognostic factors including the International Prognostic Index (IPI), bulk disease and c-MYC/8q24 gene rearrangements were analysed. Furthermore, we stratified DLBCLs as germinal centre B-cell (GCB) subtype and non-GCB subtype based on Hans’ immunohistochemical algorithm and also examined Epstein-Barr virus (EBV) status. Results Twenty-seven patients with RD-associated DLBCL were identified. Twenty patients had primary Sjogren’s syndrome, three had systemic lupus erythematosus, two had rheumatoid arthritis and two had systemic sclerosis. Secondary Sjogren’s syndrome was found in four patients. The median age at the time of diagnosis of DLBCL was 59 years with a female predominance (26:1). Based on IPI, 16 patients were assigned to the intermediate-high and high-risk groups. Bulk disease was detected in 29% of patients. Of the 20 examined cases, 4 (20%) were classified as the GCB subtype and 16 (80%) were classified as the non-GCB subtype. EBV was detected in 2 of the 21 tested cases (10%), and the c-MYC/8q24 gene rearrangement was not found in any of the 19 examined cases. After the lymphoma diagnosis, the median overall survival (OS) was 10 months (range: 0–238 months). Conclusions Except for the more common non-GCB subtype, we did not identify any other prognostic factor that could influence the prognosis of patients with RD-associated DLBCL. We believe that short OS in our patients was predominantly associated with decreased tolerance to lymphoma treatment.
Collapse
Affiliation(s)
- Vadim Gorodetskiy
- Department of Intensive Methods of Therapy, V A Nasonova Research Institute of Rheumatology, Moscow, Russian Federation
| | - Natalya Probatova
- Department of Pathology, N N Blokhin Russian Cancer Research Center, Moscow, Russian Federation
| | - Tatiana Obukhova
- Cytogenetic Laboratory, National Research Center for Hematology, Moscow, Russian Federation
| | | |
Collapse
|
5
|
Manyukhina V, Rostovtseva E, Prokofyev A, Obukhova T, Schneiderman J, Stroganova T, Orekhova E. MEG Visual Gamma Oscillations Predict Sensory Perception in Women: The Replication Study. Int J Psychophysiol 2021. [DOI: 10.1016/j.ijpsycho.2021.07.357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
6
|
Gorodetskiy V, Probatova N, Sidorova Y, Kupryshina N, Obukhova T, Vasilyev V, Ryzhikova N, Sudarikov A. The non-leukemic T cell large granular lymphocytic leukemia variant with marked splenomegaly and neutropenia in the setting of rheumatoid arthritis - Felty syndrome and hepatosplenic T cell lymphoma mask. Am J Blood Res 2021; 11:227-237. [PMID: 34322285 PMCID: PMC8303016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Received: 03/23/2021] [Accepted: 04/30/2021] [Indexed: 06/13/2023]
Abstract
T cell large granular lymphocytic (T-LGL) leukemia is a rare type of mature T cell neoplasm. The typical features of T-LGL leukemia include an increased number of large granular lymphocytes in the peripheral blood, cytopenia (most commonly neutropenia), and mild-to-moderate splenomegaly. Up to 28% of patients with T-LGL leukemia have rheumatoid arthritis (RA). This study reports ten atypical cases (seven women and three men, median age 60.5 years) of RA-associated T-LGL leukemia presenting with lymphopenia, severe neutropenia, and marked splenomegaly. The weight of the spleens ranged from 892 to 2100 g (median 1100 g). Bone marrow histology and differential counts of bone marrow aspirates revealed no peculiarities in nine of ten cases. The red pulp of the spleen was expanded and showed moderate to strong infiltration by medium-sized slightly pleomorphic lymphocytes in nine cases and subtle infiltration in one. Although lymphocytic infiltration involved both cords and sinusoids, it was more apparent within the splenic cords. The white pulp was preserved and contained prominent germinal centers in eight patients and was atrophic in two patients. Immunohistochemically, malignant lymphocytes were CD3+, CD43+, and CD4- in all cases and TIA-1+ in nine out of ten. TCRαβ positivity and TCRγδ positivity was observed in six and four cases out of ten, respectively. All ten patients had T cell clonality in the spleen tissue, but in three cases it was absent in both blood and bone marrow. STAT3 mutations in the spleen tissue were detected in three of ten cases. In all eight cases studied, neither isochromosome 7q nor trisomy 8 was detected in the spleen tissue. Cases of RA-associated T-LGL leukemia with low LGL count in the peripheral blood, neutropenia, and marked splenomegaly present a diagnostic challenge and can be misdiagnosed as Felty's syndrome or hepatosplenic T cell lymphoma.
Collapse
Affiliation(s)
- Vadim Gorodetskiy
- Department of Intensive Methods of Therapy, V. A. Nasonova Research Institute of RheumatologyMoscow, Russia
| | - Natalya Probatova
- Department of Pathology, N.N. Blokhin Russian Cancer Research CenterMoscow, Russia
| | - Yulia Sidorova
- Laboratory of Molecular Hematology, National Research Center for HematologyMoscow, Russia
| | - Natalia Kupryshina
- Hematopoiesis Immunology Laboratory, N.N. Blokhin Russian Cancer Research CenterMoscow, Russia
| | - Tatiana Obukhova
- Cytogenetic Laboratory, National Research Center for HematologyMoscow, Russia
| | | | - Natalya Ryzhikova
- Laboratory of Molecular Hematology, National Research Center for HematologyMoscow, Russia
| | - Andrey Sudarikov
- Laboratory of Molecular Hematology, National Research Center for HematologyMoscow, Russia
| |
Collapse
|
7
|
Demidova I, Barinov A, Savelov N, Gagarin I, Grinevitch V, Stroiakovaski D, Popov M, Laktionov K, Gutorov S, Smolin A, Olshanskaya Y, Obukhova T. Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and methodologic pitfalls. Arch Pathol Lab Med 2014; 138:794-802. [PMID: 24878018 DOI: 10.5858/arpa.2012-0762-oa] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
CONTEXT Echinoderm microtubule-associated protein-like 4 gene (EML4) and anaplastic lymphoma kinase gene (ALK) fusion was shown to be the driver of tumorigenesis in approximately 3% to 5% of patients with non-small cell lung cancer (NSCLC) and is associated with response to inhibition with crizotinib. However, no complete agreement regarding the best diagnostic test for identification of ALK rearrangements has been achieved yet. OBJECTIVE To investigate the concordance, sensitivity, and specificity of immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and reverse transcription-polymerase chain reaction (RT-PCR) for detection of ALK rearrangements. DESIGN Thirty-six prospectively tested patients with NSCLC who had adenocarcinoma and 10 ALK-positive samples were included in the study. All samples were tested by IHC (ALK1 clone, 5A4 clone, D5F3 clone), FISH (LSI ALK Break Apart and ALK FISH Probe), and multiplexed RT-PCR. RESULTS Immunohistochemistry staining was successful in all samples.. Clone D5F3 showed the best sensitivity and specificity of 100%; clones ALK1 and 5A4 showed sensitivities of 91% with specificity of 100%. Both FISH probes showed concordance with sensitivity and specificity of 100%. Hybridization and RT-PCR were successful in 98% and 93.4% of samples, respectively, with sensitivity of 88% and specificity of 100%. Frequent artifacts leading to misinterpretation were observed with all 3 methodologies. CONCLUSIONS All 3 methodologies showed good sensitivity, specificity, and concordance, when artifacts were characterized and excluded. However, all ambiguous cases have to be confirmed as ALK rearranged by at least 2 of the 3 methods.
Collapse
Affiliation(s)
- Irina Demidova
- From the Laboratory of Molecular Diagnostics (Drs Demidova and Gagarin and Mr Barinov), the Departments of Pathology (Drs Savelov and Grinevitch), Chemotherapy (Dr Stroiakovaski), and Thoracic Surgery (Dr Popov), Moscow Oncological Hospital 62, Moscow, Russia; the Departments of Thoracic Oncology (Dr Laktionov) and Chemotherapy (Dr Gutorov), N. N. Blokhin Russian Cancer Research Center of Russian Academy of Medical Sciences, Moscow, Russia; the Department of Radiology, N. N. Burdenko Central Military Hospital, Moscow, Russia (Dr Smolin); the Laboratory of Cytogenetics and Molecular Genetics, Russian Federal Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia (Ms Olshanskaya); and the Laboratory of Cytogenetics, Russian Scientific Center for Hematology, Moscow, Russia (Ms Obukhova)
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Baryakh E, Valiev T, Kravchenko S, Kremenetskaya A, Magomedova A, Zvonkov E, Obukhova T, Vorobjev A. P006 Burkitt lymphoma in adults: how to treat? Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70354-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
9
|
Baryakh E, Obukhova T, Domracheva E, Valiev T, Kaplanskaya I, Kravchenko S, Kremenetskaya A, Vorobjev A. P052 Cytogenetic impact in differential diagnostics of Burkitt lymphoma and other high proliferated lymphomas. Leuk Res 2007. [DOI: 10.1016/s0145-2126(07)70400-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|